RenovoRx (RNXT) Competitors $1.30 -0.02 (-1.52%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.35 +0.05 (+3.77%) As of 07/8/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNXT vs. ALMS, OGI, DRUG, LFVN, NLTX, GNFT, IMAB, CYBN, VYGR, and PBYIShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Alumis (ALMS), Organigram Global (OGI), Bright Minds Biosciences (DRUG), Lifevantage (LFVN), Neoleukin Therapeutics (NLTX), GENFIT (GNFT), I-Mab (IMAB), Cybin (CYBN), Voyager Therapeutics (VYGR), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Its Competitors Alumis Organigram Global Bright Minds Biosciences Lifevantage Neoleukin Therapeutics GENFIT I-Mab Cybin Voyager Therapeutics Puma Biotechnology RenovoRx (NASDAQ:RNXT) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk. Do analysts recommend RNXT or ALMS? RenovoRx presently has a consensus target price of $7.25, indicating a potential upside of 457.69%. Alumis has a consensus target price of $22.86, indicating a potential upside of 556.81%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than RenovoRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media prefer RNXT or ALMS? In the previous week, RenovoRx's average media sentiment score of 0.00 equaled Alumis'average media sentiment score. Company Overall Sentiment RenovoRx Neutral Alumis Neutral Is RNXT or ALMS more profitable? RenovoRx's return on equity of -119.58% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -119.58% -88.01% Alumis N/A -406.27%-107.29% Do institutionals & insiders have more ownership in RNXT or ALMS? 3.1% of RenovoRx shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 40.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, RNXT or ALMS? RenovoRx has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRx$40K1,188.53-$8.81M-$0.40-3.25AlumisN/AN/A-$294.23MN/AN/A SummaryRenovoRx and Alumis tied by winning 5 of the 10 factors compared between the two stocks. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.28M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-3.2520.8027.0020.10Price / Sales1,188.53286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book6.847.487.985.56Net Income-$8.81M-$55.04M$3.16B$248.40M7 Day PerformanceN/A2.44%2.40%4.67%1 Month Performance-5.11%1.90%2.19%6.64%1 Year Performance10.17%4.35%33.82%21.31% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx2.8703 of 5 stars$1.30-1.5%$7.25+457.7%+7.4%$48.28M$40K-3.256ALMSAlumis2.8917 of 5 stars$3.46+4.5%$22.86+560.6%N/A$188.26MN/A0.00N/AOGIOrganigram Global0.9513 of 5 stars$1.41+1.1%N/A-8.9%$188.19M$117.47M14.05860News CoverageGap DownDRUGBright Minds Biosciences2.6925 of 5 stars$26.50-3.0%$83.25+214.2%+2,446.7%$186.67MN/A-73.61N/APositive NewsLFVNLifevantage4.2731 of 5 stars$14.57+7.2%$30.50+109.3%+156.3%$183.44M$200.16M21.12260NLTXNeoleukin TherapeuticsN/A$19.50-2.9%N/A-47.0%$183.26MN/A-6.2790High Trading VolumeGNFTGENFIT1.5077 of 5 stars$3.60-1.6%$13.00+261.1%-15.4%$180M$76.77M0.00120News CoverageGap UpIMABI-Mab2.8748 of 5 stars$2.20+5.3%$6.00+172.7%+41.0%$179.65M$3.89M0.00380Gap UpCYBNCybin2.9135 of 5 stars$7.71-2.0%$86.00+1,015.4%N/A$177.52MN/A-1.7650Analyst ForecastVYGRVoyager Therapeutics3.8028 of 5 stars$3.17+4.3%$13.39+322.4%-59.2%$175.43M$80M-2.17100PBYIPuma Biotechnology3.7821 of 5 stars$3.53-0.3%$7.00+98.3%+20.5%$175.19M$230.50M4.58200 Related Companies and Tools Related Companies ALMS Alternatives OGI Alternatives DRUG Alternatives LFVN Alternatives NLTX Alternatives GNFT Alternatives IMAB Alternatives CYBN Alternatives VYGR Alternatives PBYI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNXT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNXT Stock Alerts